口服抗凝药降低卵巢癌一线化疗静脉血栓栓塞率的质量改进项目
该质量改进项目纳入2020-2025年在Sheba医疗中心接受一线化疗的卵巢癌患者,通过员工教育、电子病历整合Khorana评分、阿哌沙班处方和化疗套间问卷等干预,前瞻性评估VTE风险降低。
要点
- 卵巢癌一线化疗患者VTE发生率高,质量改进项目可显著降低VTE事件。
- 干预包括员工教育、电子病历整合Khorana评分、阿哌沙班处方和靶向问卷。
- 项目未增加出血事件或血制品消耗,安全性可接受。
核心结论
- 口服抗凝质量改进项目成功降低卵巢癌一线化疗期间的VTE事件,且未明显增加风险。
研究设计与样本
- 前瞻性质量改进项目,纳入2020-2025年Sheba医疗中心接受一线化疗的卵巢癌患者。
- 项目于2023年7月启动,包括员工教育、电子病历整合Khorana评分、阿哌沙班处方和化疗套间问卷。
- 使用MDClone®软件结合自然语言处理从电子病历影像报告中识别VTE事件。
主要发现
- 项目启动前VTE发生率为16.9%,启动后为12.5%。
- 未观察到出血事件或血制品消耗增加。
临床怎么用
- 在卵巢癌一线化疗患者中实施包含风险评估和口服抗凝处方的质量改进项目可降低VTE发生率。
局限性
- 未来工作将聚焦于改进风险分层和血栓预防的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic cancer patients receiving systemic chemotherapy face increased risks for venous thromboembolism (VTE). Benefit has been shown for prophylactic anticoagulants in risk-stratified populations. Ovarian cancer (OC) is commonly advanced at diagnosis and treated with chemotherapy. Despite high VTE rates among OC patients, predictors of risk in this population are not well studied, and information on the benefit of oral anticoagulants is lacking. OBJECTIVE: A quality improvement (QI) intervention to improve appropriate anticoagulation in risk-selected OC patients receiving first-line chemotherapy was implemented, prospectively assessing VTE risk reduction. METHODS: Patients receiving first-line chemotherapy for OC at Sheba Medical Center 2020-2025 were included. A QI program (launched 07/2023) included staff education, EMR-incorporated Khorana scoring, integrated apixaban prescriptions and targeted chemo-suite questionnaires. Data was extracted from the EMR using MDClone® software with Natural Language Processing to identify VTE events in imaging reports. Descriptive statistics were used to compare patients treated before and after program implementation. Predictors of VTE were evaluated with logistic regression. RESULTS: Patient characteristics were comparable before and after program implementation. VTE rates were high at 16.9% before, and 12.5% following roll-out. No increase in bleeding events or blood products consumption was appreciated. Program implementation was found to be a significant protective factor on multivariable analysis, adjusting for other risk factors (aOR = 0.39 (0.17-0.81), p = 0.015). CONCLUSION: The implementation of an oral anticoagulation QI program successfully decreased VTE events during first-line chemotherapy for OC with no appreciable increase in risk. Future work will focus on improved risk stratification and selection for thromboprophylaxis.
引用
- Helpman L, Josephy D, Toderis L, et al. Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer- A quality improvement project. Gynecol Oncol. 2026. PMID: 42561468. doi:10.1016/j.ygyno.2026.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。